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ABSTRACT
Diabetes is a complex disease of increasingly
common occurrence worldwide. Attaining
optimal glycemic control is the main challenge
to prevent the development of diabetes-related
complications and/or to stop their progression.
In recent years, the pharmacologic toolkit for
the treatment of diabetes has considerably
expanded, thus paving the way to more patho-
physiology-oriented therapies. For instance, the
sodium-glucose cotransporters SGLT2 and
SGLT1 have been in the spotlight because of
better knowledge of their physiology and ther-
apeutic potential. At present, whereas the
SGLT2 inhibitors are widely applied in current
clinical practice as an effective and well-toler-
ated treatment that increases the urinary
excretion of glucose, less is known about the use
of SGLT1 inhibitors. SGLT1s are of primary
importance in the small intestine, an organ that
does not express SGLT2, while in the kidney
they are expressed in the late renal proximal
tubules, where it reabsorbs the glucose escaped
from the upstream SGLT2. Hence, SGLT1-me-
diated glucose reabsorption in the kidney is
increased when the tubular glucose load over-
whelms the capacity of SGLT2 or when the lat-
ter is inhibited. The role of SGLT1 in intestinal
and renal glucose transport makes the trans-
porter a potential target for antidiabetic ther-
apy. Here, we briefly report the evidence on
LX2761, a new inhibitor against SGLT1 and
SGLT2 in vitro, which acts in vivo as a selective
inhibitor of SGLT1 in the gastrointestinal tract.
LX2761 improves glycemic control without the
glycosuria-related side effects of SGLT2 inhibi-
tors, particularly genitourinary tract infections.
However, whether it represents a valid thera-
peutic option for all patients with diabetes or is
more appropriate for specific phenotypes, e.g.,
patients with concomitant diabetes and chronic
kidney disease, who may benefit less from the
renal mechanism of selective SGLT2 inhibitors,
remains to be tested in large randomized con-
trolled trials.
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In recent years, the renal sodium/glucose
cotransporters SGLT1 and SGLT2 have gained
increasing attention from researchers and clin-
icians, given their potential role as an effective
and generally well-tolerated treatment option
for the attainment of a proper glycemic control
[1, 2]. However, the renal expression of both
SGLT2 and SGLT1 in the proximal tubule of
patients with type 2 diabetes (T2D) is still not
completely elucidated, and experimental stud-
ies from different research groups have reported
conflicting results [3–7].
In this regard, Solini et al. [3] recently
reported that the renal expression of SGLT1 in
patients with T2D was similar to that of their
normoglycemic (NG) counterparts, which also
showed higher expression of SGLT2. The
patients included in the analysis had a mean
diabetes duration of about 3 years and were on a
glucose-lowering therapy with oral hypo-
glycemic agents, without SLGT2 inhibitors and/
or insulin therapy. These observations have not
been reported by previous studies in mouse
models of diabetes [4] or in human T2D patients
[5–7]. As a potential explanation for their find-
ings, the authors found that clinical factors
such as duration of diabetes, different pharma-
cologic treatments, varying degrees of glycemic
control and the extent of renal impairment may
limit the comparability of the study findings
and may have influenced the expression of each
pair of brush border/basolateral transporters
SGLT2/GLUT2 and SGLT1/GLUT1 located,
respectively, in the S1-S2 and S3 segments of the
tubular nephron.
However, Norton et al. [7] observed that in
patients with T2D the expression of SGLT1
mRNA was increased more than fourfold in kid-
ney biopsy specimens compared to individuals
with normal glucose regulation. In this case, the
authors argued that poorer glycemic control,
older age and a decreased glomerular filtration
rate may explain, at least in part, the increased
expressionof SGLT1mRNA inpatientswith T2D.
The authors also observed significant correla-
tions of higher expression of SGLT1 mRNA with
increasing levels of fasting plasma glucose
(r = 0.63, p\0.001), post-prandial glucose
(r = 0.36, p\0.05) and glycosylated hemoglobin
(r = 0.43, p\0.01), but not with age (p = 0.21)
and bloodpressure (p = 0.82). These results are in
accordance with previous evidence on the posi-
tive correlation of glycemia and HbA1c with the
number of SGLT1 cotransporters [2, 6].
Norton et al. [7] point out that the increased
expression of SGLT1 in patients with T2D may
develop as a compensatory mechanism to
increase glucose reabsorption and could there-
fore potentially limit the efficacy of SGLT2 inhi-
bitors. Indeed, under physiologic conditions, the
SGLT2 accounts for about 95% of filtered glucose
reabsorption (160–180 g/day) in the S1 and S2
segments of the proximal tubule, while the
pharmacologic treatment with SGLT2-specific
inhibitor treatment reduces the glucose reab-
sorption by 50–70% [8]. Regarding the properties
and anatomic distribution of the SGLT1 and
SGLT2 cotransporters, it is alsoworthnoting that
SGLT2 is primarily expressed in the kidney,while
SGLT1 does not solely mediate the glucose reab-
sorption of the remaining filtered glucose (about
3–5%) in the last S3 segment of the proximal
tubule [8], but it is also themain sodium/glucose
cotransporter in the small gut. It has been
hypothesized that SGLT1 activity could be
increased as a compensatory mechanism in case
of a massive tubular glucose load overwhelming
the reabsorption capacity of the SGLT2 cotrans-
porter as happens during the supra-physiologic
glycosuria induced by glucose-lowering therapy
with SGLT2 inhibitors [8]. However, SGLT2
selective inhibitors have been reported to be less
effective in patients with moderate to severe
renal dysfunction [9], which is an issue of con-
siderable relevance considering that it affects
30–40% of all diabetic patients. In this setting,
the inhibition of SLGT1 may be a promising
option for achievingbetter glycemic control [10].
In fact, intestinal SLGT1 is responsible formost of
the glucose absorption, and its blockade induces
an increased glucose load to the distal gut [10].
This article does not contain any new studies
withhumanor animal subjects performedby any
of the authors.
SGLT1 mutations in mouse models may offer
valid examples of SGLT1 inhibition because
these phenotypes show a lack of effect of SGLT1
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in the intestinal lumen with severe osmotic
diarrhea and metabolic acidosis caused by the
non-absorbed excess of glucose [11, 12]. Of note,
the administrations of nonselective and selective
SGLT1 inhibitors in humans are not accompa-
nied by these serious adverse effects. Indeed,
sotagliflozin, also known as LX4211, a nonse-
lective SGLT2/1 inhibitor, was reported to be safe
and well tolerated (namely without gastroin-
testinal side effects) when administered to 36
patientswith T2D in a once-daily oral dose of 150
or 300 mg for 28 days [13]. The main reason for
its safety was ascribed to the incomplete inhibi-
tion of intestinal SGLT1. Similarly,
GSK-1614235, a selective SGLT1 inhibitor, has
been administered without serious safety issues
to 12 healthy subjects in a 20-mg oral dose in a
randomized controlled trial [14]. The plasma
concentrations of GSK-1614235 indicated very
low levels of the active molecule with rapid
clearance and a significant 50% glucose reab-
sorption reduction compared to placebo. In both
studies, SLGT1 inhibitor administration
obtained satisfactory glycemic control, suggest-
ing that even a low dose of SLTG1 inhibitorsmay
be sufficient to correct hyperglycemia.
According to the potential of enhanced gly-
cemic control through SGLT1 inhibition that
also avoids the glycosuria-related side effects of
SGLT2 inhibitors, particularly genitourinary
tract infections, Goodwin et al. [15] recently
reported the discovery of LX2761, a more
potent SGLT1 inhibitor restricted to the
intestinal lumen that delays intestinal glucose
absorption in vivo. The authors disclosed
LX2761 after the methyl substitution of the
xyloside core of sotagliflozin, which guaranteed
a slightly higher potency at SGLT1 and, more
importantly, compatibility with synthesis and
starting material availability. As expected with
the delayed glucose absorption that is the
prevalent mechanism of SGLT1 inhibition in
the intestine, male C57 mice treated with
LX2761 exhibited a significant increase in cecal
glucose levels and decrease in cecal pH due to
fermentation of glucose to short chain fatty
acids in the cecum. LX2761 was designed to
remain in the intestine after oral delivery to
inhibit SGLT1 locally without affecting the
SGLT1/2 mechanism in the kidney. LX2761
resulted as a chemically stable and very potent
inhibitor against SGLT1 and SGLT2 in vitro but
acted as a selective SGLT1 inhibitor in vivo in
the gastrointestinal tract. This new SLGLT1
antagonist could represent a valid therapeutic
strategy in the future for the treatment of dia-
betes, particularly in patients with renal
impairment who may benefit less from the renal
mechanism of selective SGLT2 inhibitors.
CONCLUSION
In conclusion, further randomized controlled
trials comparing the effects of selective and
nonselective SLGT1 inhibitors in patients with
T2D and concomitant chronic kidney disease
are warranted to assess the efficacy and the
safety of these drugs according to the extant
glomerular filtration rate. Indeed, further strat-
ified analyses in other subgroups of patients
with T2D are needed to better elucidate whether
those presenting with higher expression levels
of renal SGLT1 may be exposed to an increased
risk of hypoglycemia or other complications,
particularly in the context of the polypharmacy
that typically characterizes patients with T2D
and other comorbid conditions.
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